Immunohistochemical detection of X-linked inhibitor of apoptosis (XIAP) in neoplastic and other thyroid disorders

Annals of Diagnostic Pathology

Volumn 11, Issue 4, 2007, Pages 235-240

  Xiao, Guang Qian ^a   Unger, Pamela D ^a   Burstein, David E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Goiter; Hashimoto's thyroiditis; Immunohistochemistry; Insular carcinoma; Papillary thyroid carcinoma; Thyroid neoplasm; XIAP

Indexed keywords

CITRIC ACID; MONOCLONAL ANTIBODY; X LINKED INHIBITOR OF APOPTOSIS;

ANAPLASTIC CARCINOMA; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GOITER; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID CANCER; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, PAPILLARY; HUMANS; IMMUNOENZYME TECHNIQUES; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 34447285489     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2006.06.010     Document Type: Article

References (36)

1. Suzuki Y., Nakabayashi Y., Nakata K., et al. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J Biol Chem 276 (2001) 27058-27063
2. Yang Y.L., and Li X.M. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 10 (2000) 169-177
3. Amantana A., London C.A., Iversen P.L., et al. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 3 (2004) 699-707
4. Bilim V., Kasahara T., Hara N., et al. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 103 (2003) 29-37
5. Endo T., Abe S., Seidlar H.B., et al. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother 53 (2004) 770-776
6. Li J., Sasaki H., Sheng Y.L., et al. Apoptosis and chemoresistance in human ovarian cancer: is Xiap a determinant?. Biol Signals Recept 9 (2000) 122-130
7. Nemoto T., Kitagawa M., Hasegawa M., et al. Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol 76 (2004) 253-259
8. Ramp U., Krieg T., Caliskan E., et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 35 (2004) 1022-1028
9. Schultz I.J., Kiemeney L.A., Witjes J.A., et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23 (2003) 3327-3331
10. Shiraki K., Sugimoto K., Yamanaka Y., et al. Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int J Mol Med 12 (2003) 705-708
11. Cao C., Mu Y., Hallahan D.E., et al. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 23 (2004) 7047-7052
12. Roa W.H., Chen H., Fulton D., et al. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. Clin Invest Med 26 (2003) 231-242
13. Tamm I., Richter S., Scholz F., et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. Hematol J 5 (2004) 489-495
14. Muris J.J., Cillessen S.A., Vos W., et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 105 (2005) 2916-2923
15. Ekedahl J., Joseph B., Grigoriev M.Y., et al. Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res 279 (2002) 277-290
16. Liu S.S., Tsang B.K., Cheung A.N., et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 37 (2001) 1104-1110
17. Rutherford T., O'Malley D., Makkenchery A., et al. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to second-line chemotherapy [abstr]. Proc Am Assoc Cancer Res 95 (2004) A4457
18. Sapi E., Alvero A.B., Chen W., et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 14 (2004) 567-578
19. Fukushima T., Suzuki S., Mashiko M., et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22 (2003) 6455-6457
20. Nikiforov Y.E. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13 (2002) 3-16
21. Cheung C.C., Boerner S.L., MacMillan C.M., et al. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am J Surg Pathol 24 (2000) 1622-1626
22. Schlumberger M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 22 Suppl (1999) 3-7
23. Burstein D.E., Nagi C., Wang B.Y., et al. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto's thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol 35 (2004) 465-473
24. Sheils O., Smyth P., Finn S., et al. RET/PTC rearrangements in Hashimoto's thyroiditis. Int J Surg Pathol 10 (2002) 167-168
25. Arif S., Blanes A., and Diaz-Cano S.J. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 41 (2002) 357-362
26. Arscott P.L., Stokes T., Myc A., et al. Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. J Clin Endocrinol Metab 84 (1999) 4246-4252
27. Di Pasquale M., Rothstein J.L., and Palazzo J.P. Pathologic features of Hashimoto's-associated papillary thyroid carcinomas. Hum Pathol 32 (2001) 24-30
28. Holcik M., Yeh C., Korneluk R.G., et al. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 19 (2000) 4174-4177
29. Holcik M., Gibson H., and Korneluk R.G. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 6 (2001) 253-261
30. Bannerji R., Kitada S., Flinn I.W., et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 21 (2003) 1466-1471
31. Ahmad M., and Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene 19 (2000) 3363-3371
32. Bhojani M.S., Rossu B.D., and Rehemtulla A. TRAIL and anti-tumor responses. Cancer Biol Ther 2 Suppl 1 (2003) S71-S78
33. de Matos P.S., Ferreira A.P., de Oliveira Facuri F., et al. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 47 (2005) 391-401
34. Weber K.B., Shroyer K.R., Heinz D.E., et al. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122 (2004) 524-531
35. Carcangiu M.L., Zampi G., and Rosai J. Poorly differentiated (insular) thyroid carcinoma. A reinterpretation of Langhans "wuchernde struma". Am J Surg Pathol 8 (1984) 655-668
36. Ain K.B. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8 (1998) 715-726